Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 69 Records) |
| Query Trace: Breast Neoplasms and CDK4[original query] |
|---|
| Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis. Cancers 2022 8 14 (16): . Rossi Tania, Angeli Davide, Tebaldi Michela, Fici Pietro, Rossi Elisabetta, Rocca Andrea, Palleschi Michela, Maltoni Roberta, Martinelli Giovanni, Fabbri Francesco, Gallerani Giul |
| Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. Breast (Edinburgh, Scotland) 2022 11 66 255-261. Zhou Jinmei, Wu Xuexue, Zhang Huiqiang, Wang Xiaobo, Yuan Yang, Zhang Shaohua, Jiang Zefei, Wang T |
| APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. JCO precision oncology 2022 10 6 e2200149. Sammons Sarah, Raskina Kira, Danziger Natalie, Alder Laura, Schrock Alexa B, Venstrom Jeffrey M, Knutson Keith L, Thompson E Aubrey, McGregor Kim, Sokol Ethan, Chumsri Saran |
| Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors. Frontiers in oncology 2022 10 12 986674. Guan Yin, Wang Yutong, Li Hongxia, Meng Jing, You Xia, Zhu Xiaofeng, Zhang Qin, Sun Tingting, Qi Chuang, An Guangyu, Fan Ying, Xu Bing |
| Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Annals of oncology : official journal of the European Society for Medical Oncology 2023 9 . F André, F Su, N Solovieff, G Hortobagyi, S Chia, P Neven, A Bardia, D Tripathy, Y-S Lu, A Lteif, T Taran, N Babbar, D Slamon, C L Artea |
| Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 9 167 115479. Elena Peruzzi, Lorenzo Gerratana, Marcella Montico, Bianca Posocco, Serena Corsetti, Michele Bartoletti, Sara Gagno, Marco Orleni, Elena De Mattia, Massimo Baraldo, Erika Cecchin, Fabio Puglisi, Giuseppe Toffoli, Rossana Ronca |
| Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis. Frontiers in oncology 2023 9 13 1192946. Ta-Chung Chao, Yi-Fang Tsai, Chun-Yu Liu, Pei-Ju Lien, Yen-Shu Lin, Chin-Jung Feng, Yen-Jen Chen, Jiun-I Lai, Chih-Yi Hsu, Jiun Jen Lynn, Chi-Cheng Huang, Ling-Ming Tse |
| Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Annals of oncology : official journal of the European Society for Medical Oncology 2023 8 . K Jhaveri, L D Eli, H Wildiers, S A Hurvitz, A Guerrero-Zotano, N Unni, A Brufsky, H Park, J Waisman, E S Yang, I Spanggaard, S Reid, M E Burkard, S Vinayak, A Prat, M Arnedos, F-C Bidard, S Loi, J Crown, M Bhave, S A Piha-Paul, J M Suga, S Chia, C Saura, J Á Garcia-Saenz, V Gambardella, M J de Miguel, E N Gal-Yam, A Rapael, S M Stemmer, C Ma, A B Hanker, D Ye, J W Goldman, R Bose, L Peterson, J S K Bell, A Frazier, D DiPrimeo, A Wong, C L Arteaga, D B Sol |
| Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors. International journal of molecular sciences 2023 7 24 (14): . Jesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, Igor López-Cade, Víctor Lorca, Alejandro Pascual, Alicia de Luna, Carmen Ramírez-Ruda, Jennifer Swindell, Paloma Flores, Ana Lluch, David W Cescon, Pedro Pérez-Segura, Alberto Ocaña, Frederick Jones, Fernando Moreno, Vanesa García-Barberán, José Ángel García-Sáe |
| Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. Genome medicine 2023 7 15 (1): 55. Yeon Hee Park, Seock-Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon-La Choi, Won-Chul Lee, Ahrum Min, Vinicius Bonato, Seri Park, Sripad Ram, Dae-Won Lee, Ji-Yeon Kim, Su Kyeong Lee, Won-Woo Lee, Jisook Lee, Miso Kim, Hyun Seon Kim, Scott L Weinrich, Han Suk Ryu, Tae Yong Kim, Stephen Dann, Yu-Jin Kim, Diane R Fernandez, Jiwon Koh, Shuoguo Wang, Song Yi Park, Shibing Deng, Eric Powell, Rupesh Kanchi Ravi, Jadwiga Bienkowska, Paul A Rejto, Woong-Yang Park, Zhengyan K |
| Clinical and Genomic Characteristics of Patients with HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 6 . Xi Rao, Yongmei Chen, Julie Beyrer, Emily Nash Smyth, Claudia Morato Guimaraes, Lacey M Litchfield, Lee Bowman, Garreth W Lawrence, Amit Aggarwal, Fabrice And |
| Alternating 17?-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 6 OF1-OF7. Gary N Schwartz, Peter A Kaufman, Karthik V Giridhar, Jonathan D Marotti, Mary D Chamberlin, Bradley A Arrick, Grace Makari-Judson, Matthew P Goetz, Shannon M Soucy, Fred Kolling, Eugene Demidenko, Todd W Mill |
| Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO precision oncology 2023 5 7 e2200531. Lorenzo Gerratana, Andrew A Davis, Marko Velimirovic, Carolina Reduzzi, Katherine Clifton, Leslie Bucheit, Whitney L Hensing, Ami N Shah, Tania Pivetta, Charles S Dai, Paolo D'Amico, Firas Wehbe, Arielle Medford, Seth A Wander, William J Gradishar, Amir Behdad, Cynthia X Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanil |
| Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. British journal of cancer 2023 4 . Frenel J-S, Lusque A, Delaloge S, Ferrero J-M, Bachelot T, Desmoulins I, Levy C, Eymard J-C, Gonçalves A, Patsouris A, Reynier M A Mouret, Thery M J-C, Petit T, Cabel L, Uwer L, Debled M, Chevrot M, Mailliez A, Jacot W, de La Motte Rouge |
| Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future oncology (London, England) 2023 4 . Nicholas Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, Cynthia X Ma, Erica L Mayer, Yeon Hee Park, Steven Fox, Xiaochun Liu, Sasha McClain, Francois-Clement Bida |
| HR/HER2 de novo metastatic breast cancer: a true peculiar entity? Drugs in context 2023 3 12 . Torrisi Rosalba, Jacobs Flavia, Miggiano Chiara, De Sanctis Rita, Santoro Arman |
| p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancer. JNCI cancer spectrum 2023 2 . Mouron Silvana, Bueno Maria J, Muñoz Manuel, Torres Raul, Rodríguez Sandra, Apala Juan V, Silva Jorge, Sánchez-Bayona Rodrigo, Manso Luis, Guerra Juan, Rodriguez-Lajusticia Laura, Malon Diego, Malumbres Marcos, Quintela-Fandino Migu |
| Prevalence and prognosis of PIK3CA mutations in Bulgarian patients with metastatic breast cancer receiving endocrine therapy in first-line setting. Cancer reports (Hoboken, N.J.) 2023 12 e1966. R Gencheva, M Petrova, P Kraleva, S Hadjidekova, M Radanova, N Conev, D Stoyanov, J Arabadjiev, E Tazimova, S Bachurska, M Eneva, M Tsvetkova, G Zhbantov, T Karanikolova, D Manov, A Ivanova, M Taushanova-Hadjieva, R Staneva, E Dimitrova, I Don |
| Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. The oncologist 2023 11 . Jiun-I Lai, Ting-Hao Kuo, Kuan-Jung Huang, Laura Min Xuan Chai, Mei-Hsuan Lee, Chun-Yu Liu, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Cheng-Chih Hsu, Ta-Chung Ch |
| Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene 2023 1 . Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra M-A, Delaloge S, Robert L, Cottu P, Pierga J Y, Loirat D, Bertucci A, Renouf B, Bidard F C, Lerebours |
| Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 1 . Davis Andrew A, Luo Jingqin, Zheng Tiantian, Dai Chao, Dong Xiaoxi, Tan Lu, Suresh Rama, Ademuyiwa Foluso O, Rigden Caron, Rearden Timothy P, Clifton Katherine, Weilbaecher Katherine, Frith Ashley, Tandra Pavankumar K, Summa Tracy, Haas Brittney, Thomas Shana, Hernandez-Aya Leonel F, Peterson Lindsay L, Wang Xiaohong, Luo Shujun J, Zhou Kemin, Du Pan, Jia Shidong, King Bonnie L, Krishnamurthy Jairam, Ma Cynthia |
| PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer. Cancer medicine 2024 9 13 (17): e70101. Eduardo Terán, Rebeca Lozano, César A Rodríguez, Mar Abad, Luis Figuero, José Antonio Muñoz, Belén Cigarral, Aline Rodrígues, Magdalena Sancho, M Asunción Gómez, Daniel Morchón, Juan Carlos Montero, José María Sayagués, M Dolores Ludeña, Emilio Fonse |
| Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer. International journal of cancer 2024 8 . Charlotte K Kindt, Carla L Alves, Sidse Ehmsen, Amalie Kragh, Thomas Reinert, Marianne Vogsen, Annette R Kodahl, Jeanette D Rønlev, Dilan Ardik, Anna L Sørensen, Kirstine Evald, Mia L Clemmensen, Johan Staaf, Henrik J Ditz |
| Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors. British journal of cancer 2024 8 . Marie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, Constance Lamy, Magali Lacroix-Triki, Thomas Bachelot, Thomas Filleron, Ludovic Lacroix, Alicia Tran-Dien, Pascal Jézéquel, Marjorie Mauduit, Janice Barros Monteiro, Marta Jimenez, Stefan Michiels, Valery Attignon, Isabelle Soubeyran, Keltouma Driouch, Nicolas Servant, Christophe Le Tourneau, Maud Kamal, Fabrice André, Ivan Bièc |
| Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes. Breast cancer research : BCR 2024 7 26 (1): 118. Arun Kadamkulam Syriac, Nitish Singh Nandu, Allison Clark, Mehrad Tavallai, Dexter X Jin, Ethan Sokol, Kimberly McGregor, Jeffrey S Ross, Natalie Danziger, Jose Pablo Leo |
| Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis. Frontiers in oncology 2024 6 14 1408664. Marcin Kubeczko, Anna Polakiewicz-Gilowska, Katarzyna ?widerska, Aleksandra Le?niak, Marta Mianowska-Malec, Barbarba ?anoszka, Konstanty Chomik, Barbara Grandys, Natalya Lisovska, Barbara Bobek-Billewicz, Ewa Chmielik, Micha? Jarz |
| APOBEC3 mutagenesis drives therapy resistance in breast cancer. bioRxiv : the preprint server for biology 2024 5 . Avantika Gupta, Andrea Gazzo, Pier Selenica, Anton Safonov, Fresia Pareja, Edaise M da Silva, David N Brown, Yingjie Zhu, Juber Patel, Juan Blanco-Heredia, Bojana Stefanovska, Michael A Carpenter, Xin Pei, Denise Frosina, Achim A Jungbluth, Marc Ladanyi, Giuseppe Curigliano, Britta Weigelt, Nadeem Riaz, Simon N Powell, Pedram Razavi, Reuben S Harris, Jorge S Reis-Filho, Antonio Marra, Sarat Chandarlapa |
| Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer. Signal transduction and targeted therapy 2024 12 9 (1): 345. Zongbi Yi, Kaixiang Feng, Dan Lv, Yanfang Guan, Youcheng Shao, Fei Ma, Binghe |
| Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet. Oncology 2024 12 25 (12): e629-e638. Hope S Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruiz-Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas Turner, Nickolas Sophos, Juan Pablo Zarate, Christina Arce, Yu-Ming Shen, Stuart Turner, Hemanth Kanakamedala, Wei-Chun Hsu, Stephen Ch |
| A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors. Biomedicines 2024 10 12 (10): . Alessandra Virga, Caterina Gianni, Michela Palleschi, Davide Angeli, Filippo Merloni, Roberta Maltoni, Paola Ulivi, Giovanni Martinelli, Ugo De Giorgi, Sara Bravacci |
- Page last reviewed:Feb 1, 2024
- Content source: